Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of mosunetuzumab + polatuzumab vedotin versus rituximab + gemcitabine + oxaliplatin in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
CTR20231513Phase 3Active
- Sponsor
- Roche
- Start
- Jul 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mosunetuzumab, polatuzumab vedotin in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, follicular lymphoma, transformed (t-FL), follicular lymphoma (FL), sponsored by Roche. Started Jul 2023; status: active.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma, transformed (t-FL)follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20231513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231513.